Related Experiment Video
Updated: Jan 21, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice
Rimas V Lukas1, Maciej M Mrugala1
1University of Chicago, Department of Neurology (R.V.L.); University of Washington, Department of Neurology (M.M.M.).
Abstract:
The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.
Insights
This review examines FDA-approved and NCCN-recommended treatments for low- and high-grade gliomas. It details systemic therapies like temozolomide and local treatments such as tumor-treating fields for primary brain tumors.
Area of Science:
- Neuro-oncology
- Oncology
- Clinical Neurology
Background:
- Management of low- and high-grade infiltrating gliomas presents daily challenges in neuro-oncology.
- Anaplastic and low-grade primary brain tumors require careful treatment considerations.
Purpose of the Study:
- To review current therapeutic strategies for infiltrating gliomas.
- To focus on treatments approved by the FDA and/or included in NCCN Guidelines.
Main Methods:
- Evaluation of systemic therapy trials including temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV).
- Assessment of local therapy trials, including surgical interventions with carmustine wafers and tumor-treating fields.
- Discussion of pivotal trials and correlative studies in primary brain tumor treatment.
Main Results:
- Systemic agents like temozolomide and PCV show efficacy in glioma treatment.
- Local therapies, including carmustine wafers and tumor-treating fields, offer alternative management options.
- Pivotal trials provide evidence for various treatment modalities in gliomas.
Conclusions:
- The therapeutic landscape for gliomas is dynamic, with evolving treatment options.
- FDA-approved and NCCN-guided therapies form the basis of current clinical decision-making.
- Continued research and evaluation of pivotal trials are crucial for advancing glioma management.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Pivot Bearings
A pivot bearing is a specialized type of bearing designed to support axial loads on a rotating shaft. The bearing surface, or the pivot, is positioned at the end of a shaft to support the axial thrust. The pivot may...
Statistical Software for Data Analysis and Clinical Trials
Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia
Role of Affect in Interpersonal Attraction

